Clinical Trial | By Ferencik M, Mayrhofer T, Bittner DO et al.
Coronary Atherosclerotic Precursors of Acute Coronary Syndromes
Can Biomarkers of Myocardial Injury Provide Complementary Information to Coronary Imaging?
Heart Failure and Atrial Fibrillation, Like Fire and Fury
Review Article | By MA Carlisle, M Fudim, AD DeVore et al.
Heart failure and atrial fibrillation are 2 common cardiovascular disorders that frequently complicate one another and exert a significant detrimental effect on cardiovascular health and well-being. Both heart failure and atrial fibrillation continue to increase in prevalence as the risk factors underlying each condition become more common. This review encompasses what is currently known about the epidemiology and pathophysiolog...
Review Article | By Mohiaddin H, Wong TDFK, Burke-Gaffney A et al.
Original Research | By Buiten RA, Ploumen EH, Zocca P et al.
IMPORTANCE - Stenting small-vessel lesions has an increased adverse cardiovascular event risk. Very thin-strut or ultrathin-strut drug-eluting stents might reduce this risk, but data are scarce. OBJECTIVE - To assess the outcome of all-comer patients with small coronary vessel lesions treated with 3 dissimilar types of drug-eluting stents. DESIGN - This is a prespecified substudy of the Compari...
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
Original Research | By SS Anand, JW Eikelboom, COMPASS Trial Investigators.
BACKGROUND - The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that the combination of low-dose rivaroxaban and aspirin reduced major vascular events in patients with stable vascular disease. OBJECTIVES- The purpose of this study was to identify subsets of patients at higher risk of recurrent vascular events, which may help focus the use of rivaroxaba...
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?
Editorial | By KM Ziada; DJ Moliterno et al.
Since evidence of increased risk of stent thrombosis with first-generation drug-eluting stents surfaced in 20051,2 and the US Food and Drug Administration advised interventional cardiologists to use dual antiplatelet therapy (DAPT) for 12 months following implantation of drug-eluting stents, the appropriate duration of DAPT has been widely studied and hotly debated. Dual antiplatelet therapy consists of concurrent administrati...